Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium.
D006801:Humans; D013810:Therapeutic Equivalency; D013959:Thyroid Diseases / Q000188:drug therapy*; D013974:Thyroxine / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards*
D013974:Thyroxine